摘要
为了探讨B细胞淋巴瘤临床病理特征,应用组织形态学和免疫组织化学分析73例B细胞淋巴瘤患者的病理资料,同时行CD20、CD3、CD5、CD23、CD30、CD79α、TdT、Bcl-2、CyclinD1、Lysozyme和Ki-67的免疫表型测定,并根据WHO新分类重新分类。73例B细胞淋巴瘤患者中,弥漫性大B细胞淋巴瘤(DLBCL)38例(52.05%),包括中心母细胞型(CB)27例,免疫母细胞型(IB)5例,间变型(AV)4例,富于T细胞或组织细胞型2例;滤泡性淋巴瘤(FL)18例,黏膜相关淋巴组织型边缘区B细胞淋巴瘤9例,套细胞淋巴瘤(MCL)2例,B淋巴母细胞性淋巴瘤(B-LBL)4例,B小淋巴细胞淋巴瘤(B-SLL)2例。B细胞淋巴瘤低度恶性组Ki-67阳性率为20.69%(6/29),高度恶性组阳性率为75%(33/44),P<0.01。初步研究结果提示,WHO新分类对B细胞淋巴瘤的诊断便于掌握,实用性强,与临床治疗和预后判断有密切关系。通过标准的形态学和一套规范的免疫组化检测,结合WHO新分类可应用于B细胞淋巴瘤的诊断和预后。
The objective of this study was to explore the clinicopathological characteristics of B-cell lymploma.The morphologic observation of HE and immunohistochemical analyses of CD20,CD3,CD5,CD23,CD30,CD79α,TdT,Bcl-2,CyclinD1,Lysozyme and Ki-67 antibody were performed in 73 cases of B-cell lymphomas.All the cases were classified according to the new WHO classification of non-Hodgkin＇s lymphoma.Among them,the most frequent type was diffuse large B-cell lymphoma（38/73,52.05%）,which was classified as following four variants： 27 cases of centroblastic variant（CB）,5 cases of immunoblastic variant（IB）,4 cases of anaplastic variant（AV）,2 cases of T-cell/histiocyte-rich variant.There was a significant difference in the frequency of Ki-67 expression between low and grade-grade lymphomas,P〈0.01.In conclusion,the new WHO classification of B-cell lymphomas is practical and easily applicable for routine pathology diagnosis,which has a close relevance with clinic-therapy and prognosis.According to the new WHO classification,morphologic studies and IHC analyses using a panel of antibodies are recommended in order to make diagnosis and prognosis.
出处
《中华肿瘤防治杂志》
CAS
2008年第18期1423-1424,共2页
Chinese Journal of Cancer Prevention and Treatment
基金
福建省卫生厅青年基金项目(2005-2-24)
